Skip to main content
TipRanks
Go Ultimate75% OFF

Lucid Diagnostics (LUCD) Q3 2026 Earnings Report

618 Followers

LUCD Q3 2026 EPS Results

Actual EPS
-$0.06
Consensus EPS
-$0.06
Beat/Miss
Missed by -$0.00
One Year Ago EPS
-$0.10

LUCD Q3 2026 Revenue Results

Actual Revenue
$1.20M
Expected Revenue
$1.63M
Beat/Miss
Missed by -$428.00K
YoY Revenue Growth
-0.66%

Earnings Announcement Details

Quarter
Q3 2026
Date
11/12/2026
Time
Before Open
Conference Call
Thursday, November 12, 2026
LUCD Upcoming Earnings

Lucid Diagnostics's next earnings date is estimated for March 29, 2027, based on past reporting schedules.

Q3 2026 Earnings Call Audio

LUCD Q3 2026 Earnings Call
0:00 / 0:00

Q3 2026 Earnings Slide Deck

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Nov 12, 2026|% Change Since:-2.36%|
Earnings Call Sentiment|Positive

The call was strongly optimistic, centered on Medicare reimbursement through Novitas, record October volume, rapidly improving Medicare activity, available operating capacity, and the potential for commercial acceleration. The company still faces a pending MolDX LCD, a substantial historical gap between billings and collections, insurance claim denials, ongoing cash burn, operating losses, and financing-related share issuance, but management characterized the reimbursement breakthrough and early fourth-quarter momentum as transformational.

Company Guidance

Lucid expects a very solid fourth quarter, strong momentum entering what it expects to be a transformational 2027, and further commercial coverage policy wins this quarter and into the new year; it expects by the end of the year to have a total of 5 Concert client plans, including the 3 previously reported, covering nearly all commercial lives in Minnesota. The company is targeting the approximately 30 million-patient EsoGuard risk population, of which approximately 50% are of Medicare age, and plans to shift Medicare volume from the historic 10% to 15% toward the 50% target population represents and perhaps even higher, using its approximately 30 sellers to drive productivity before adding sales infrastructure. October exceeded 1800 tests, versus the 2500 to 3000 quarterly range previously targeted, and the company expects to be aggressive but responsible while seeking a revenue trajectory that can drive its burn rate down in the immediate term; Medicare claims are paid at the $1940 per-test rate, and the next patient contributes about 90%.

  • Medicare Reimbursement for EsoGuardMedicare claims submitted from Lucid's Texas laboratory to the Novitas MAC have been consistently paid since late September, with every Medicare claim allowed to date paid at the established clinical laboratory fee schedule rate of $1,940 per test. Management described this as a major breakthrough enabling nationwide access for Medicare beneficiaries and allowing immediate commercialization without waiting for the MolDX LCD.
  • Record October Test Volume and Early Commercial MomentumOctober was a record month for test volume, with more than 1,800 tests performed. Management said the commercial transition toward Medicare patients was producing very strong early momentum six weeks after implementation and expected a very solid fourth quarter.
  • Medicare Volume Scaling RapidlyMedicare represented approximately 16% of third-quarter test volume, or about 450 tests. In the first month of the fourth quarter, the team achieved nearly 70% of that prior-quarter Medicare volume, representing more than 300 Medicare tests, while the commercial team was still early in the transition.
  • Large Addressable Medicare OpportunityThe company estimates an EsoGuard testing population of approximately 30 million patients recommended for esophageal precancer testing, with approximately 50% of that population at Medicare age. Management is targeting a rapid increase in Medicare's share of total volume from the historical 10% to 15% range toward the approximately 50% represented by the target population.
  • Commercial Execution InitiativesLucid implemented geographic positioning of sales and clinical resources, updated compensation plans, data-driven routing, local physician partnerships, and creative programs to identify and engage at-risk Medicare patients. The regular sales team is operating under a common Medicare-focused strategy, with approximately 30 sellers currently in the field.
  • Capacity Available for GrowthManagement said growth is not currently limited by laboratory capacity, including at the Texas laboratory. Manufacturing capacity for EsoCheck and the EsoGuard collection kit is also scalable with short lead times, and the clinical specialist team is positioned to scale as needed.
  • Third-Quarter Test Volume StabilityThe sales team sold 2,870 tests in the third quarter, with a billable value of approximately $7.9 million. Volume increased approximately 4% sequentially and approximately 1% year over year, remaining within the targeted 2,500 to 3,000 range for the transitional reimbursement period.
  • Improving Revenue per Test and Insurance AllowablesYear-to-date revenue per test was $446, compared with $383 for all of 2025, a 17% improvement. The average insurance allowable amount for successful claims increased to $1,700 per test in the third quarter from $1,420 in the second quarter, up approximately 19%, and exceeded the year-to-date average of $1,600.
  • Operating Expense Reduction and Unit EconomicsTotal operating expenses were $13.5 million, down approximately 6% from $14.3 million in the second quarter. Non-GAAP operating expenses were $11.8 million versus $12.3 million in the second quarter and below the prior four-quarter average of $12.4 million. At approximately $2,000 per test, management said the next patient contributes about 90%, with EsoCheck manufacturing costs under $60 and laboratory processing costs of roughly $120 per test.
  • Additional Financing and Cash PositionCash at September 30 was $18 million. The October 21 Series C convertible preferred offering generated $15 million of gross proceeds, bringing pro forma cash to approximately $33 million. Management said the recent $50 million financing provides sufficient runway to drive commercial acceleration and revenue growth.
  • Commercial Coverage ExpansionLucid expects Concert Laboratory Benefit Manager's coverage policy to be adopted by five client plans by year-end, including the three previously reported. Beginning the following month, those plans are expected to provide coverage to nearly all commercial lives in Minnesota. Management also expects additional commercial coverage policy wins this quarter and into the new year.
  • Guideline and Coding ProgressThe American Gastroenterological Association released draft updated guidelines for public comment that name EsoGuard and EsoCheck as an alternative to endoscopy and rate them as having a high certainty of evidence. Lucid said it is the only commercially available test cited in the draft guidelines. A new Category 3 CPT code and an ICD-10 diagnosis code linked to a positive EsoGuard result were also issued to facilitate tracking, billing, and follow-up endoscopy documentation.
  • VA Program ProgressLucid's first two VA programs are up and running, with a robust pipeline of additional centers. The company said its engagement with dozens of VA systems and physicians remains strong and expects the VA to be a meaningful long-term contributor to commercial activity and revenue.
  • Medicare Payment Predictability and Revenue RecognitionNovitas was described as paying consistently week over week, and sometimes twice per week. Medicare claims from the Texas laboratory are now predictable enough to be recognized upon report delivery, whereas most other claims continue to be recognized when collected.
  • Expected Commercial AccelerationManagement said Medicare reimbursement has changed what is possible for Lucid, with the company entering a new chapter focused on commercial acceleration and revenue growth. The company expects strong momentum entering what it described as a transformational 2027.

LUCD Earnings History

LUCD earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Mar 29, 20272026 (Q4)-0.06--0.1――
Nov 12, 20262026 (Q3)-0.06-0.06-0.140.00% (+0.04)
Aug 13, 20262026 (Q2)-0.06-0.06-0.140.00% (+0.04)
May 14, 20262026 (Q1)-0.06-0.07-0.1656.25% (+0.09)
Mar 26, 20262025 (Q4)-0.09-0.10-0.1947.37% (+0.09)
Nov 12, 20252025 (Q3)-0.10-0.10-0.250.00% (+0.10)
Aug 13, 20252025 (Q2)-0.11-0.10-0.250.00% (+0.10)
May 14, 20252025 (Q1)-0.15-0.16-0.9983.84% (+0.83)
Mar 24, 20252024 (Q4)-0.18-0.19-1.3385.71% (+1.14)
Nov 13, 20242024 (Q3)-0.21-0.20-0.229.09% (+0.02)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed